Literature DB >> 19653346

Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma.

Ke-Cheng Xu1, Li-Zhi Niu, Qiang Zhou, Yi-Ze Hu, De-Hong Guo, Zheng-Ping Liu, Bing Lan, Feng Mu, Ying-Fei Li, Jian-Sheng Zuo.   

Abstract

AIM: To evaluate the efficacy of sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery for unresectable hepatocellular carcinoma (HCC).
METHODS: Four hundred and twenty patients were enrolled in this study. The patients, who were considered to have unresectable tumors due to their location or size or comorbidity, were divided into sequential TACE-cryosurgery (sequential) group (n = 290) and cryosurgery alone (cryo-alone) group (n = 130). Patients in the sequential group tended to have larger tumors and a greater number of tumors than those in the cryo-alone group. Tumors larger than 10 cm in diameter were only seen in the sequential group. TACE was performed with the routine technique and percutaneous cryosurgery was conducted under the guidance of ultrasound 2-4 wk after TACE.
RESULTS: During a mean follow-up period of 42 +/- 17 mo (range, 24-70 mo), the local recurrence rate at the ablated area was 17% for all patients, 11% and 23% for patients in sequential group and cryo-alone groups, respectively (P = 0.001). The overall 1-, 2-, 3-, 4- and 5-year survival rate was 72%, 57%, 47%, 39% and 31%, respectively. The 1- and 2-year survival rates (71% and 61%) in sequential group were similar to those (73% and 54%) in cryo-alone group (P = 0.69 and 0.147), while the 4- and 5-year survival rates were 49% and 39% in sequential group, higher than those (29% and 23%) in cryo-alone group (P = 0.001). Eighteen patients with large HCC (> 5 cm in diameter) survived for more than 5 years after sequential TACE while no patient with large HCC (> 5 cm in diameter) survived more than 5 years after cryosurgery. The overall complication rate was 24%, and the complication rates were 21% and 26% for the sequential and cryo-alone groups, respectively (P = 0.06). The incidence of hepatic bleeding was higher in cryo-alone group than in sequential group (P = 0.02). Liver crack only occurred in two patients of the cryo-alone group.
CONCLUSION: Pre-cryosurgical TACE can increase the cryoablation efficacy and decrease its adverse effects, especially bleeding. Sequential TACE and cryosurgery may be the better procedure for unresectable HCC, especially for large HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19653346      PMCID: PMC2721242          DOI: 10.3748/wjg.15.3664

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Minimally invasive cryosurgery--technological advances.

Authors:  J Baust; A A Gage; H Ma; C M Zhang
Journal:  Cryobiology       Date:  1997-06       Impact factor: 2.487

2.  Transcatheter hepatic arterial embolization in the treatment of hepatocellular carcinoma.

Authors:  Y F Liaw; D Y Lin
Journal:  Hepatogastroenterology       Date:  1990-10

Review 3.  Intraoperative monitoring and postoperative imaging of hepatic cryosurgery.

Authors:  W H Brewer; R S Austin; G W Capps; J P Neifeld
Journal:  Semin Surg Oncol       Date:  1998-03

4.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

5.  Cryosurgical ablation of hepatic tumors.

Authors:  K A Crews; J A Kuhn; T M McCarty; T L Fisher; R M Goldstein; J T Preskitt
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

6.  Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.

Authors:  M Uchida; H Kohno; H Kubota; T Hayashi; A Yamanoi; T Kimoto; T Ono; N Nagasue
Journal:  World J Surg       Date:  1996 Mar-Apr       Impact factor: 3.352

7.  Prognostic factors for cryotherapy of colorectal liver metastases.

Authors:  J K Seifert; Th Junginger
Journal:  Eur J Surg Oncol       Date:  2004-02       Impact factor: 4.424

8.  Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma.

Authors:  Y Q Yu; D B Xu; X D Zhou; J Z Lu; Z Y Tang; P Mack
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

9.  Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer.

Authors:  R Yamada; K Kishi; M Sato; T Sonomura; N Nishida; K Tanaka; Y Shioyama; M Terada; M Kimura
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

10.  A pig model of hepatic cryotherapy. In vivo temperature distribution during freezing and histopathological changes.

Authors:  Joachim K Seifert; Claus D Gerharz; Frank Mattes; Fatma Nassir; Karsten Fachinger; Christoph Beil; Theodor Junginger
Journal:  Cryobiology       Date:  2003-12       Impact factor: 2.487

View more
  14 in total

Review 1.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

2.  [Cryoablation - back again?].

Authors:  P Isfort; T Penzkofer; A H Mahnken
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

Review 3.  Current State of Tumor Ablation Therapies.

Authors:  Christopher W Bailey; Malcolm K Sydnor
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 4.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 5.  Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.

Authors:  Andrew R Lewis; Carlos A Padula; J Mark McKinney; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

6.  Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: a review.

Authors:  Lemore Carmi; Christos Georgiades
Journal:  Semin Intervent Radiol       Date:  2010-09       Impact factor: 1.513

7.  Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation.

Authors:  Ji-Bing Chen; Jia-Liang Li; Li-Hua He; Wei-Qun Liu; Fei Yao; Jian-Ying Zeng; Yi Zhang; Ke-Qiang Xu; Li-Zhi Niu; Jian-Sheng Zuo; Ke-Cheng Xu
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 8.  Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors.

Authors:  Hyeon Yu; Charles T Burke
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

9.  Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma.

Authors:  Yongping Yang; Chunping Wang; Yinying Lu; Wenlin Bai; Linjing An; Jianhui Qu; Xudong Gao; Yan Chen; Lin Zhou; Yu Wu; Yongyi Feng; Minna Zhang; Xiujuan Chang; Jiyun Lv
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-11       Impact factor: 7.027

10.  Clinical outcome, proteome kinetics and angiogenic factors in serum after thermoablation of colorectal liver metastases.

Authors:  Marieke W J L A E Wertenbroek; Marianne Schepers; Hannetta J Kamminga-Rasker; Jan T Bottema; Anneke C Muller Kobold; Han Roelofsen; Koert P de Jong
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.